Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  DBV Technologies    DBV   FR0010417345

DBV TECHNOLOGIES

(DBV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

European ADRs Move Higher in Tuesday Trading

01/19/2021 | 11:12am EST


© MT Newswires 2021
All news about DBV TECHNOLOGIES
03/05DBV TECHNOLOGIES  : to Participate in the H.C. Wainwright Global Life Sciences C..
GL
03/04European ADRs Edge Lower in Thursday Trading
MT
03/03DBV Technologies Announces Date Change for Reporting Full Year 2020 Financial..
GL
03/03DBV TECHNOLOGIES  : Provisional calendar
CO
03/01DBV Technologies to Report Full Year 2020 Financial Results on March 4, 2021
GL
02/24DBV TECHNOLOGIES  : to Participate in Upcoming AAAAI 2021 Congress
GL
02/22DBV TECHNOLOGIES  : Names Chief Legal Officer
MT
02/22DBV TECHNOLOGIES  : Announces Appointment of Michele F. Robertson as Chief Legal..
GL
02/19DBV TECHNOLOGIES  : to Participate in SVB Leerink Global Partners Healthcare Con..
AQ
02/12European ADRs Move Higher in Friday Trading
MT
More news
Financials
Sales 2020 14,8 M 17,5 M 17,5 M
Net income 2020 -166 M -197 M -197 M
Net cash 2020 124 M 147 M 147 M
P/E ratio 2020 -2,35x
Yield 2020 -
Capitalization 500 M 593 M 593 M
EV / Sales 2020 25,5x
EV / Sales 2021 23,8x
Nbr of Employees 311
Free-Float 92,1%
Chart DBV TECHNOLOGIES
Duration : Period :
DBV Technologies Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DBV TECHNOLOGIES
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 8,15 €
Last Close Price 9,11 €
Spread / Highest target 20,8%
Spread / Average Target -10,5%
Spread / Lowest Target -37,4%
EPS Revisions
Managers and Directors
NameTitle
Daniel Tassé Chief Executive Officer & Executive Director
Sébastien Robitaille Chief Financial Officer
Michel de Rosen Non-Executive Chairman
Bertrand Dupont Chief Technology Officer
Pharis Mohideen Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
DBV TECHNOLOGIES94.07%550
CSL LIMITED-13.13%86 600
WUXI BIOLOGICS (CAYMAN) INC.-21.35%48 530
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.12.26%43 599
SAMSUNG BIOLOGICS CO.,LTD.-15.74%42 055
BIOGEN INC.10.56%41 239